Press Releases

Meeting Launch date is Saturday, June 13th 2020 at 9:00am (PT)

More than 1,140 patients randomized and topline results expected in second half 2020

Pharmacokinetic comparison of STS101, an intranasal dry powder formulation of dihydroergotamine, with other intranasal, injectable and oral inhaled DHE formulations

STS101 EMERGE™ Phase 3 efficacy trial remains on track with announcement of topline data expected in second half of 2020

On track to announce topline data in second half of 2020 from Phase 3 EMERGE™ efficacy trial evaluating STS101 for the acute treatment of migraine

Completed upsized initial public offering of $90.8 million in gross proceeds

-- Favorable Pharmacokinetic, Safety, and Tolerability Results Support Advancing STS101 into Pivotal Phase 3 Efficacy Trial

-- Commercial leader brings recent migraine space experience to Satsuma as it advances lead product candidate STS101 into Phase 3 development --

Funding supports Phase 3 development of STS101 for the acute treatment of migraine, including pivotal Phase 3 efficacy trial with planned initiation in Q3 2019

- STS101 for the acute treatment of migraine demonstrates highly differentiated pharmacokinetic (PK) profile in Phase 1 clinical trial

-- $12 Million Series A financing supports development of best-in-class therapy for acute migraine that incorporates novel and proprietary SNBL nasal drug delivery technology --